Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Lucence logo — Overcoming cancer through earlier detection

Lucence

Overcoming cancer through earlier detection

Founded 2016 United States Palo Alto, United States 111 employees Series A Total: $29.20M Biotechnology, Health Care

General Information

Company Name Lucence
Founded Year 2016
Location United States Palo Alto, United States
Employees 111
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B2C, B2B, DaaS
Revenue Model Service Fee, One Time Purchase, Tiered Pricing
Social

BounceWatch is an independent company data service, not affiliated with Lucence. To contact Lucence, visit lucence.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lucence compare?

A PDF of Lucence and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lucence soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lucence

Lucence, founded in 2016, is a pioneering venture in the Biotechnology and Health Care industries. The company stands out with its mission of Overcoming cancer through earlier detection. By leveraging proprietary AI-powered liquid biopsy technology, Lucence aims to detect cancers at an earlier stage, drastically improving patient outcomes.

Headquartered in both the United States and Singapore, Lucence operates through its twin CLIA-licensed laboratories, enhancing its capacity to provide personalized cancer care services internationally. This strategic geographic positioning enables it to serve a global market, tapping into cutting-edge healthcare innovation hubs.

The company's robust growth trajectory was underlined by a significant $20.00M Series A investment received on 01 November 2019. Notable investors include SGInnovate, Heliconia Capital, IHH Healthcare, Boon Hwee Koh, and Lim Kaling, indicating strong confidence in Lucence's technological potential and market strategy.

Business keywords: Precision Health, Liquid Biopsy, AI-powered Technology, Cancer Detection, Personalized Cancer Care, Early Cancer Detection, Targeted Cancer Treatment, Proprietary Technology, Medical Diagnostics, CLIA-licensed Laboratories, Healthcare Innovation, Cancer Screening

Services & Products

LiquidHALLMARKse
LucenceINSIGHTse
CardioHemeRISK19
LucenceLONGEVITY19
HemeMARK19
UNITED 600
UNITED CNS
Rapid TissueMARK19

Target Customers

Oncologists Primary Care Doctors Patients Insurers Investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $20.00M 5
SGInnovate Heliconia Capital IHH Healthcare
SGInnovate, Heliconia Capital +3
01 Nov 2019
Seed $9.20M 3
Heliconia Capital
Heliconia Capital, Boon Hwee Koh +1
01 Jan 2019
Spinout Undisclosed 1
A*STAR
A*STAR
01 Apr 2016

Lucence Alternatives & Competitors

View All Alternatives
Lucence vs
VisionGate, Inc.
VisionGate, Inc. United States

Leading the Battle Against Lung Cancer through our Early Detection Technology

Venture round
24 employees
Biotechnology, Health Care
Lucence vs
CellMax Life
CellMax Life United States

Liquid biopsy company focused on cancer screening with a proprietary platform for detecting precance...

25 employees
Biotechnology, Health Care
Lucence vs
Foresight Diagnostics (a Natera company)
Foresight Diagnostics (a Natera company) United States

Precision medicine company dedicated to improving the lives of cancer patients through improved canc...

Acquired
112 employees
Biotechnology, Health Care
View all alternatives

FAQ About Lucence

Overcoming cancer through earlier detection
Lucence was founded in 2016.
Lucence is headquartered in Palo Alto, United States.
Lucence operates in Biotechnology and Health Care. Its work centres on Precision Health, Liquid Biopsy, AI-powered Technology and Cancer Detection. Its customers include Oncologists, Primary Care Doctors and Patients.
Lucence has a B2B2C, B2B and DaaS business model. Its revenue comes from Service Fee, One Time Purchase and Tiered Pricing.
Lucence has approximately 111 employees.
Lucence has completed 3 funding rounds, raising a total of $29.20M. The latest funding stage is Series A.
Lucence offers: LiquidHALLMARKse, LucenceINSIGHTse, CardioHemeRISK19, LucenceLONGEVITY19, HemeMARK19, UNITED 600, UNITED CNS, Rapid TissueMARK19, LucenceMONITOR19.
Top alternatives and competitors to Lucence include VisionGate, Inc., CellMax Life, Foresight Diagnostics (a Natera company), Exai Bio, OncoDNA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lucence and VisionGate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lucence, https://bouncewatch.com/company/lucence, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes